Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$153.56 USD

153.56
472,339

+0.72 (0.47%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $153.57 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication

AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.

Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY

Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.

INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare

Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.

Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks

With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.

Chemed (CHE) Up 5.7% Since Last Earnings Report: Can It Continue?

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio

Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.

Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen

Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.

Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance

PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.

Quest Diagnostics (DGX) Up 6.3% Since Last Earnings Report: Can It Continue?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardinal Health (CAH) to Open New Distribution Center in Ohio

Cardinal Health's (CAH) new center is set to integrate cutting-edge technology and automation, enhancing efficiency, storage capacity and quality of service.

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.

Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS

PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.

Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch

Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.

Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment

Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.

Omnicell (OMCL) Introduces Central Med Automation Service

Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.

Brookdale (BKD) Down 7% Since Q2 Earnings Miss on Lower Interest

Brookdale (BKD) expects adjusted EBITDA for the third quarter in the range of $90-$95 million.

GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare

GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.

Boston Scientific (BSX), Silk Road Merger Delayed for Review

Boston Scientific (BSX) withdraws its premerger notification and report form to give the U.S. FTC more time to review the proposed acquisition of Silk Road Medical.

Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene

Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.

Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed

Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.

NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up

NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.

Paragon 28 (FNA) Expands SMART 28 Ecosystem With New Launches

Paragon 28 (FNA) strengthens its position in the foot and ankle device market with the launch of the SMART28 Case Management Portal and the SMART Bun-Yo-Matic device.